An interesting post from accross the pond (click to link) from Epilepsytalk on new developments in medication for uncontrolled seizures.
A new type of anti-epilepsy medication that selectively targets proteins in the brain, controlling excitability, has been developed by Johns Hopkins led researchers.
The purpose of this revolutionary new drug is to significantly reduce seizure frequency in people whose recurrent seizures have been resistant to even the latest medications.
In a multinational, blinded, placebo-controlled trial of more than 700 people with uncontrolled partial-onset seizures, roughly one-third of participants saw the frequency of their seizures fall by more than 50 percent when they were given 8 milligrams a day of Perampanel. Those in this trial typically had about 10 seizures a day!
The participants in the study, reported in the journal Neurology, were all taking one to three anti-epileptic drugs before adding Perampanel (or a placebo) to their regimen.
Perampanel (Fycompa) is the first product in this class, because of its success inhibiting the excess activity of a glutamate receptor (AMPA) in…
View original post 462 more words